Actos (Pioglitazone) Regulatory Status, US, EU, Canada, UK

What Is Pioglitazone and How Does It Work?

Pioglitazone is a thiazolidinedione that selectively activates peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear transcription factor expressed predominantly in adipose tissue, liver, and skeletal muscle. This single mechanistic target drives meaningful improvements in peripheral insulin sensitivity and hepatic glucose output, which explains both its glucose-lowering efficacy and its hepatic anti-inflammatory effects relevant to NASH.

PPARγ Activation: The Core Mechanism

When pioglitazone binds PPARγ, the receptor heterodimerizes with retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of insulin-responsive genes. The downstream effects include upregulation of GLUT4 (glucose transporter type 4) in muscle and adipose tissue, suppression of hepatic gluconeogenic enzymes, and redistribution of fatty acids from visceral to subcutaneous depots [1].

Adiponectin secretion rises substantially. A 2003 study in Diabetes (N=90) documented a 54% mean increase in serum adiponectin after 12 weeks of pioglitazone 30 mg daily, and higher adiponectin correlated directly with HOMA-IR improvement [2]. That adiponectin signal is one reason pioglitazone reduces hepatic steatosis even in patients whose HbA1c is already reasonably controlled.

Effects on Lipid Metabolism

Pioglitazone also activates PPARα to a modest degree. This dual activity shifts lipoprotein metabolism: triglycerides typically fall 9 to 26% and HDL-cholesterol rises 12 to 19% at therapeutic doses (15 to 45 mg/day) [3]. LDL particle size shifts from small, dense atherogenic particles toward larger, more buoyant ones, even though LDL-C may rise slightly.

Mechanism Relevance to NASH

The liver-directed effects of PPARγ activation, including reduced de novo lipogenesis, suppressed NF-κB-driven hepatic inflammation, and improved free fatty acid oxidation, provide the biological rationale for pioglitazone's use in non-alcoholic steatohepatitis. PIVENS (N=247, NEJM 2010) demonstrated histologic NASH resolution in 47% of pioglitazone-treated patients versus 22% on placebo [4]. That 25-percentage-point absolute difference, while not reaching the pre-specified primary endpoint for the combined histologic score, established pioglitazone as the most evidence-backed pharmacologic option for biopsy-proven NASH prior to the 2024 FDA approval of resmetirom.

US FDA Regulatory Status

Pioglitazone received FDA approval on July 15, 1999, under NDA 021073, for the adjunctive treatment of type 2 diabetes mellitus in adults. The original approval covered Actos (Takeda) at 15 mg, 30 mg, and 45 mg oral tablets taken once daily, with or without food [5].

Label Revisions and Safety Communications

The FDA label has undergone several significant revisions since 1999:

• 2007: Boxed warning added for congestive heart failure risk, reflecting the class-wide fluid retention liability of TZDs.
• 2010: The FDA reviewed the PROactive trial (N=5,238) data suggesting a possible bladder cancer signal. PROactive, published in The Lancet (2005), was designed primarily for cardiovascular outcomes but collected bladder cancer cases as an adverse event [6].
• June 2011: The FDA issued a safety communication stating that use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. The label was updated to include this warning and to contraindicate use in patients with active bladder cancer [5].
• 2016: An FDA update reviewed the 10-year Kaiser Permanente Northern California cohort study (N=193,099 diabetes patients) and concluded the bladder cancer association remained plausible but modest, with an adjusted hazard ratio of 1.06 (95% CI: 0.89 to 1.26) for any use and 1.40 (95% CI: 1.03 to 1.91) for the longest duration or highest cumulative dose group [7].

The FDA has not withdrawn pioglitazone from the US market. It remains Schedule IV prescription-only. Generic versions entered the US market in August 2012 following Takeda's exclusivity expiration, and more than a dozen manufacturers currently hold ANDAs.

Off-Label Use in NASH: The FDA Position

The FDA has not approved pioglitazone specifically for NASH. The 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance states: "Pioglitazone is recommended for use in patients with biopsy-proven NASH, including those without diabetes, given the strong evidence for histologic benefit." That guideline endorsement gives clinicians a defensible off-label basis under FDA rules, because prescribing an approved drug off-label is legal when supported by credible evidence. Prescribers should document the PIVENS data and the AASLD guidance in the patient record.

EU European Medicines Agency (EMA) Regulatory Status

The EMA granted centralized marketing authorization for Actos in October 2000 via the centralized procedure, applicable across all EU member states. The approved indication mirrors the FDA's: monotherapy or combination therapy for type 2 diabetes mellitus in adults when diet and exercise alone are insufficient [8].

Bladder Cancer Review and Restrictions (2011)

In July 2011, the EMA's Committee for Medicinal Products for Human Use (CHMP) completed a review of the bladder cancer signal and concluded that the benefits of pioglitazone continue to outweigh risks for most patients, but added requirements for:

1. A contraindication in patients with current or past history of bladder cancer.
2. A contraindication in patients with uninvestigated macroscopic haematuria.
3. Mandatory prescriber and patient information materials (a Risk Minimisation Measure under EU pharmacovigilance regulations).

The CHMP also required a 5-year follow-up observational study in the EU. Results from the ENCePP-registered EPIC cohort confirmed a modest elevated risk (adjusted relative risk approximately 1.22 for ever-use versus never-use of pioglitazone in diabetic patients) [9].

France and Germany: Divergent National Responses

This is where EU regulatory history gets clinically instructive. France's ANSM (Agence nationale de sécurité du médicament) suspended pioglitazone in June 2011, ahead of the EMA's formal conclusion, based on data from a French national cohort of approximately 1.5 million patients. ANSM's analysis found an adjusted odds ratio of 1.22 (95% CI: 1.05 to 1.43) for bladder cancer with pioglitazone use [9]. France partially lifted the suspension in 2013 but maintained restrictions limiting new prescriptions to patients with no alternative treatment options and requiring annual reassessment.

Germany's BfArM did not suspend pioglitazone but issued strengthened prescriber guidance aligned with the EMA's 2011 CHMP conclusions. German prescriptions declined sharply through 2013 to 2016 but have partially recovered as diabetes guidelines continued to include TZDs for specific patient subgroups.

The divergence between France's suspension and Germany's guidance-only approach illustrates a genuine tension in EU pharmacovigilance: centralized EMA approval does not preclude member-state emergency restrictions under Article 107i of Directive 2001/83/EC, which France invoked. Clinicians practicing in EU countries should verify their national competent authority's current guidance, not just the EMA label, before initiating pioglitazone.

Canada: Health Canada Regulatory Status

Health Canada approved pioglitazone under DIN 02243187 in 2000 for the brand Actos (Takeda Canada Inc.). The approved indication covers type 2 diabetes mellitus as monotherapy or in combination with metformin, a sulfonylurea, or insulin [10].

Canadian Safety Advisories

Health Canada issued a safety communication in September 2011 updating the Actos Product Monograph to include:

• A warning regarding the increased risk of bladder cancer with long-term use (greater than 12 months).
• A contraindication in patients with active bladder cancer or a history of bladder cancer.
• A requirement to avoid use in patients with uninvestigated macroscopic haematuria.

Health Canada referenced Canadian epidemiologic data from the Manitoba Centre for Health Policy and parallel analysis from the BC Cancer Agency, both showing hazard ratios in the 1.15 to 1.30 range for bladder cancer with cumulative pioglitazone exposure exceeding 24 months [10].

Generic pioglitazone entered the Canadian market following patent expiration, and multiple generic DINs are currently active. Pioglitazone is not included on the Canadian federal formulary but appears on several provincial formularies (Ontario ODB, BC PharmaCare) with special authorization criteria.

NASH Use in Canada

Canada's Canadian Association for the Study of the Liver (CASL) has not issued a standalone NASH pharmacotherapy guideline as of mid-2025, but the 2021 Canadian Liver Meeting consensus acknowledged pioglitazone as an option for biopsy-proven NASH based on PIVENS data. Off-label prescribing in Canada follows a similar framework to the US: physician judgment, informed consent, and documentation of evidence basis.

UK: MHRA Regulatory Status

The UK Medicines and Healthcare products Regulatory Agency (MHRA) retained pioglitazone's marketing authorization following the UK's exit from the European Medicines Agency framework on January 1, 2021. The product license number PL 00156/0131 (Actos 30 mg) and related strengths remain active on the UK register [11].

Post-Brexit Regulatory Maintenance

Under the UK's "grandfathering" of EU approvals active at the Brexit transition date, pioglitazone did not require a separate UK marketing authorization application. The MHRA has since conducted its own pharmacovigilance reviews and, as of the 2023 MHRA Drug Safety Update database, pioglitazone's label in the UK mirrors the EMA's 2011 restrictions: bladder cancer contraindication, haematuria contraindication, and annual benefit-risk reassessment recommendation for long-term users.

Northern Ireland continues to follow EMA rules under the Windsor Framework, so pioglitazone in Northern Ireland is governed by the EMA's current label rather than the MHRA's Great Britain label. This creates a small but real prescribing asymmetry within the UK that practitioners in Northern Ireland should track.

NICE Guidance on Pioglitazone

The National Institute for Health and Care Excellence (NICE) technology appraisal TA298 (2013, updated 2016) covers TZDs in type 2 diabetes. NICE does not recommend pioglitazone as first-line therapy. It is positioned as a third-line or combination option when metformin and a sulfonylurea are contraindicated or not tolerated, and when SGLT-2 inhibitors or GLP-1 receptor agonists are also not appropriate. NICE explicitly references the bladder cancer risk when outlining patient selection.

Comparative Regulatory Status: Head-to-Head Table

| Jurisdiction | Approval Year | Approving Body | Bladder Cancer Warning Added | Suspension or Restriction | Current Status | |---|---|---|---|---|---| | United States | 1999 | FDA | 2011 | None | Active (generics dominant) | | European Union | 2000 | EMA | 2011 | France suspended 2011, partial lift 2013 | Active with restrictions | | Canada | 2000 | Health Canada | 2011 | None | Active (provincial formularies vary) | | United Kingdom | 2000 (EU); retained 2021 | MHRA | 2011 (EU); retained | None (NICE restricts to third-line) | Active |

Key Clinical Trial Evidence Across Jurisdictions

Regulatory decisions in all four jurisdictions have been shaped by the same core evidence base. Understanding that base is clinically necessary.

PIVENS (NEJM 2010)

The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) enrolled 247 adults without diabetes and with biopsy-proven NASH [4]. Patients received pioglitazone 30 mg/day, vitamin E 800 IU/day, or placebo for 96 weeks.

Key results:

• NASH resolution (defined by histologic improvement in NAS score with no worsening of fibrosis): 47% pioglitazone vs. 22% placebo (P<0.001 for the secondary endpoint).
• Fibrosis improvement: 37% pioglitazone vs. 22% placebo (P = 0.08, non-significant).
• Weight gain: mean 4.7 kg with pioglitazone vs. 0.5 kg placebo.

The trial did not reach its primary endpoint (a composite histologic score requiring improvement across multiple domains), which is why pioglitazone did not receive FDA approval for NASH. The secondary endpoint results, however, became the principal evidence anchor for off-label prescribing in all four jurisdictions.

PROactive (Lancet 2005)

PROactive (N=5,238) randomized patients with type 2 diabetes and macrovascular disease to pioglitazone 45 mg or placebo for a mean 34.5 months [6]. The primary composite cardiovascular endpoint did not reach statistical significance (HR 0.90, 95% CI 0.80 to 1.02, P = 0.095). The secondary main composite endpoint (death, non-fatal MI, or stroke) did reach significance (HR 0.84, 95% CI 0.72 to 0.98, P = 0.027).

PROactive also generated the initial bladder cancer case count that triggered the FDA and EMA reviews in 2010 to 2011. Fourteen bladder cancer cases occurred in the pioglitazone group vs. Six in placebo (not statistically significant in isolation but enough to prompt post-marketing surveillance requirements).

The Kaiser Permanente Cohort (2016)

Lewis et al. (2015, BMJ, N=193,099) conducted a 10-year retrospective cohort examining pioglitazone and bladder cancer in a US insured population [7]. The adjusted HR for bladder cancer with any pioglitazone use was 1.06 (95% CI: 0.89 to 1.26). Among the highest cumulative dose and duration group (over 96,000 mg total), the HR rose to 1.40 (95% CI: 1.03 to 1.91). The FDA cited this study directly in its 2016 label update.

Dosing, Contraindications, and Prescriber Considerations Across Markets

Approved Doses

All four jurisdictions approve the same dose range: 15 mg, 30 mg, and 45 mg once daily, with titration guided by glycemic response and tolerability. Maximum dose is 45 mg/day in all jurisdictions. When used with insulin, the EMA and Health Canada labels recommend an insulin dose reduction of 10 to 25% to reduce hypoglycemia risk.

Shared Contraindications (All Four Jurisdictions)

1. Active bladder cancer or history of bladder cancer.
2. Symptomatic heart failure (NYHA Class III or IV) or any heart failure in the EMA label.
3. Severe hepatic impairment.
4. Pregnancy and breastfeeding.
5. Diabetic ketoacidosis.

Jurisdiction-Specific Nuances

The EMA label adds a contraindication for uninvestigated macroscopic haematuria (requiring urologic workup before initiation). The FDA label does not formally contraindicate pioglitazone in NYHA Class I to II heart failure but does require careful monitoring and avoidance if the patient develops fluid retention signs. The MHRA label aligns with the EMA on the haematuria contraindication.

Bone Fracture Risk

All four labels now include a warning regarding increased fracture risk in women, based on pooled data showing fracture rates approximately twice as high in women taking pioglitazone compared with active comparators (incidence rate approximately 2.6 per 100 patient-years vs. 1.3) [12]. Prescribers should assess bone mineral density and fall risk, particularly in postmenopausal women.

Off-Label NASH Prescribing: Evidence Threshold and Clinical Workflow

Pioglitazone's off-label use in NASH is arguably its most active prescribing frontier in 2024 to 2025, particularly for patients who cannot access or afford resmetirom (Rezdiffra, approved by the FDA in March 2024 for NASH with moderate-to-advanced fibrosis at $47,400 per year list price).

For NASH prescribing, a defensible clinical workflow includes:

1. Biopsy confirmation of NASH (NAS score 4 or above) or strong non-invasive confirmation (FIB-4 index above 2.67 plus MRI-PDFF above 5%).
2. Exclusion of bladder cancer risk factors (smoking history, prior pelvic radiation, occupational chemical exposure) and haematuria workup if needed.
3. Dose selection: PIVENS used 30 mg/day; some hepatologists escalate to 45 mg/day in patients without fluid retention.
4. Weight monitoring: anticipate 3 to 5 kg weight gain over 6 to 12 months and address proactively with dietary counseling.
5. Duration planning: PIVENS ran 96 weeks; shorter courses are unlikely to deliver durable histologic benefit. Annual reassessment of benefit versus bladder cancer risk is standard in all four jurisdictions.
6. HbA1c monitoring even in non-diabetic NASH patients, as pioglitazone may lower fasting glucose and cause symptomatic hypoglycemia when combined with caloric restriction.

The 2023 AASLD Practice Guidance explicitly states that pioglitazone "is recommended for patients with biopsy-proven NASH, with or without type 2 diabetes," citing a high level of evidence (Level I, Grade A recommendation) for histologic improvement [13].